December 10, 2020 10:32 AM ESTUpdated January 11, 09:49 PM
R&D

An­gling for a spot among the gi­ants, TG Ther­a­peu­tics touts PhI­II MS da­ta for CD20 drug

Amber Tong

While the phar­ma gi­ants duke it out in mul­ti­ple scle­ro­sis, a biotech is tak­ing a crack at the shak­ing up the mar­ket. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Chas­ing the next wave of obe­si­ty drugs, Met­sera files for an IPO

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Lil­ly fi­nances new $500M biotech fund man­aged by a16z

Ex­clu­sive: Mod­er­na's for­mer top sci­en­tist has a new start­up us­ing AI to im­prove mR­NA ther­a­pies

Ab­b­Vie writes off $3.5B on Cerev­el drug af­ter Phase 2 fail­ures

A service from the Financial Times